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Summary
Objective: This study sought to use a systematic review to ascertain the efﬁcacy and safety of hyaluronic acid (HA) in the treatment of hip
osteoarthritis (OA).
Design: A protocolized search was made of a number of electronic databases, including Medline, EMBASE, Cochrane Library and Health
Technology Assessment (HTA) among others. Two independent reviewers applied a series of inclusion and exclusion criteria to the studies
located in the search, and selected only those that included more than 20 patients; had a follow-up period of more than 1 week; and exclu-
sively assessed the efﬁcacy and/or effectiveness of HA in patients with conﬁrmed hip OA.
Results: A total of eight studies, comprising clinical trials and one review, met the inclusion criteria, and had study populations ranging from 22
to 104 patients. Only two of the trials were controlled: one compared two HAs of different molecular weights; and the other compared HA with
corticoids and a placebo. Relief of pain was estimated to be around 40e50% by most studies, though the duration of this post-treatment effect
was not known.
Conclusions: Based on available evidence, HA treatment should only be used under careful supervision by the clinician and just in those
cases where other treatments have failed in hip OA. There are methodologic limitations displayed in the literature, which were mainly the ab-
sence of a control group in most of the studies, overly short follow-up periods, and different ways of measuring outcomes.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most frequent disease of the loco-
motor system, with radiological changes being observed in
70%of subjects over 50 years of age1. It can affect any joints,
but those most frequently affected are the hands, knee, hip,
and spine. The prevalence of hip OA is slightly lower than
that of knee OA, and, while it is more frequent in males under
50 years of age, above this age the proportion becomes in-
verted, with the disease becomingmore frequent in women2.
The risk factors that favor the appearance of hip OA can be
divided into modiﬁable and non-modiﬁable: modiﬁable fac-
tors include body mass index, type of occupational activity,
sports activity, previous traumatisms, alterations in the align-
ment of the lower limbs, and bone mineral density; non-mod-
iﬁable factors are sex, age and genetic factors.
Hyaluronic acid (HA) is an organic polysaccharide widely
distributed throughout the body, forming part of various tis-
sues but fundamentally the connective tissue. Initially used
in temporomandibular joint OA3,4 and then in knee OA, it
has subsequently been introduced in hip OA, shoulder OA,
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Received 24 May 2006; revision accepted 8 August 2006.1and more recently, OA of the trapezio-metacarpal joint5.
The route of administration in treatment of OA is intraarticu-
lar. Produced by the chondrocytes and synoviocytes of the
synovial membrane, HA is found dissolved in the synovial
liquid and forms part of the extracellular matrix of hyaline
cartilage. Since HA concentration in the articular liquid of ar-
thritic joints is reduced, intraarticular HA treatment designed
to increase its concentration is known as viscosupplementa-
tion. Most guidelines recommend the use of paracetamol or
nonsteroidal anti-inﬂammatory drugs (NSAIDs) for symp-
tomatic treatment of OA6,7. As longer-term treatment, the
use of glucosamine, chondroitin sulfate and diacerein (this
one is not available in USA but can be used in the European
Union) has become widespread, with glucocorticoids being
another possible intraarticular treatment. HA has been
used less often in hip OA, due fundamentally to the fact
that the hip is a less easily accessible joint than the knee.
This study thus sought to use a systematic review to an-
alyze the efﬁcacy and safety of HA in intraarticular treat-
ment of hip OA.
Methods
BIBLIOGRAPHIC SEARCH
The following databases were searched for information:
Medline (Pubmed); EMBASE (Silver Platter); Cochrane306
1307Osteoarthritis and Cartilage Vol. 14, No. 12Collaboration; ISI Web of Knowledge; Lilacs (Literatura Lat-
inoamericana en Ciencias de la Salud e Latin American
Health Science Literature); and CRD databases (Centre
for Review and Dissemination, University of York), which in-
cludes the DARE (Database of Abstracts of Reviews of Ef-
fectiveness), NHS EDD (National Health Service Economic
Evaluation Database) and HTA (Health Technology
Assessment) databases. The databases consulted in order
to locate ongoing clinical trials and research projects in-
cluded clinicaltrials.gov, Center Watch, CCT (Current Con-
trolled Trials), National Research Register, Refer, CRISP
(Computer Retrieval of Information on Scientiﬁc Projects),
the European Union CORDIS (Community Research & De-
velopment Information Service) and CSIC (Consejo Supe-
rior de Investigaciones Cientı´ficas, Spain’s Scientiﬁc
Research Board).
INCLUSION AND EXCLUSION CRITERIA
The papers retrieved in the search were selected accord-
ing to the following inclusion criteria: (1) based on design
and type of publication, systematic reviews, meta-analyses,
clinical trials, cohort studies, caseecontrol studies and case
series were included, with all other types of studies being
excluded; (2) based on sample size, studies with 20 or
more patients were included. In the case of comparative
studies, studies with a minimum of 20 patients in each
arm were included; (3) based on the designated study ob-
jective, studies that analyzed the efﬁcacy and safety of
treatment with intraarticular HA in hip OA were included,
with those that merely described HA administration tech-
nique being excluded; (4) based on language, studies pub-
lished in English, Spanish, Portuguese, French and Italian
were included; (5) based on outcome variable, account
was solely taken of studies that assessed changes in pain
and quality of life; and (6) based on length of the follow-
up period, studies with follow-up periods of more than 1week were included. Studies conducted on animals were
excluded.
Based on the abstracts yielded by the search, papers
were selected by two reviewers in accordance with the
above inclusion and exclusion criteria. The papers were
then critically perused and data extracted, using purpose-
made data-extraction tables.
Study quality was assessed by reference to study design,
in accordance with the United States Preventive Services
Task Force classiﬁcation8.
Results
A total of seven clinical trials and one review met the in-
clusion criteria and were duly included in this review. With
the single exception of a US study, all the others were
from Europe. The studies were published from 1994
through 2005 and had sample sizes ranging from 22 to
104 patients. The follow-up period varied among the stud-
ies, as did the time point at which outcomes were assessed
during follow-up. The longest follow-up was 1 year and the
shortest was 3 months. In all, ﬁve studies used high- and
three studies used low-molecular-weight HA. Figure 1 pro-
vides a description of the follow-up period, type of HA
used, and number of patients included in each study.
Shown in Table I are the main characteristics of each of
the studies included.
Therewere ﬁve studies that had no comparison group9e13.
In all, HA treatment led to improvement in degree of pain,
ranging from 84% (at 12 months) in the study by Vad
et al.12 to 43% at 3 months in the study by Conrozier
et al.11. In Bragantini and Molinaroli9 and Brocq et al.10 stud-
ies, treatments concomitant with HA were allowed (NSAIDs
or symptomatic slow acting drugs in OA, SYSADOAs), and
in Vad et al.12 study the patients also participated in an exer-
cise program. Improvements in joint function, measuredAuthor n 15 days 1 month 2 months 3 months 6 months 12 months
Bragantini 44
Brocq
Conrozier  57
Vad 22
Berg 31 28 16
Tikiz 26
Qvistgaard 33 29
43
22 22
49
22
25
22 18
36 33
32 26
Spaces correspond to assessment visits.
High-molecular-weight hyaluronic acid
Low-molecular-weight hyaluronic acid
Corticosteroids
Saline serum
Fig. 1. Description of follow-up period, type of HA, and number of patients in the studies included.
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Description of primary studies included in the systematic review
Reference Design and
follow-up period
Setting and
sample size
Main outcomes Remarks Grade of
evidence
Bragantini
and Molinaroli9
Uncontrolled
clinical trial
Italy Signiﬁcant relief of
pain at 30 days
and at 6 months
NSAIDs or analgesics
permitted
II-3
6 months 44 patients Signiﬁcant improvement
in difﬁculty in walking
at 6 months
Six patients treated
in both hips
50 hips treated No differences in
consumption of
analgesics and
NSAIDs
Evidence of conﬂict
of interests
Brocq
et al.10
Uncontrolled
clinical trial
France 59% of patients
responded at 30
days(50%
reduction in pain)
SYSADOAs, analgesics
and NSAIDs permitted.
Patients with Kellgren
and Lawrence grade I
included
II-3
6 months 22 patients No conﬂict of interests
Conrozier
et al.11
Uncontrolled
clinical trial
France Patients experienced
signiﬁcant improvement
in terms of pain (43%),
WOMAC (28.1%), and
overall patient
self-assessment (38.1%)
Non-uniform doses: 25
patients received one
and 32 two injections
II-3
3 months 57 patients Evidence of conﬂict
of interests
Vad
et al.12
Uncontrolled
clinical trial
USA 84% improvement in
pain at 12 months
(90.5% in moderate OA
and 50% in severe OA)
Patients received an
exercise program
for 4e6 weeks
after treatment
II-3
12 months 22 patients No conﬂict
of interests
Berg and
Olsson13
Uncontrolled
clinical trial
Sweden Signiﬁcant reduction
in pain at 2 weeks,
maintained at 3 months.
55% response (OARSI
criteria) at 3 months,
and 44% in patients
assessed in the
extended study
Only patients that
responded at 3 months
passed through to
the extended study
phase
II-3
3 months 28 patients No conﬂict of interests
Extension to 6e11
months in the event
of response at 3 months
16 included in the
extended study
Tikiz
et al.14
Controlled, randomized,
double-blind clinical trial
in two groups that
compared two HAs of
different molecular
weights
Turkey No differences between
the two groups in terms
of reduction of pain,
WOMAC, and
Lequesne’s index
Patients in the two
groups treated
in both hips
I
6 months 43 patients: 25 treated
with low-molecular-
weight HA and 18 with
high-molecular-
weight HA
No conﬂict
of interests
Qvistgaard
et al.15
Controlled, randomized,
double-blind clinical trial
in three groups (HA,
corticoids and placebo)
Denmark No signiﬁcant differences
at 3 months with
respect to pain,
WOMAC, Lequesne’s i
ndex, and overall
patient self-assessment.
Patients with Kellgren
and Lawrence
grades I and
IV included
I
3 months 104 patients (34 HA,
34 corticoids and 36
placebo)
Evidence of
conﬂict of interests
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Osteoarthritis Index (WOMAC) questionnaire or Lequesne’s
index, were likewise observed in all ﬁve studies. These im-
provements ranged from 28% in the study by Conrozier
et al., using theWOMACquestionnaire11, to 59% in the study
by Brocq et al., using Lequesne’s index10.
The two studies that had a comparison group were pub-
lished in 2005. One14 included 43 and the other 104 pa-
tients15. In the study by Tikiz et al.14 two HAs of different
molecular weights were compared, and in the study by
Qvistgaard et al.15 a low-molecular-weight HA was com-
pared with corticoids and placebo. In Tikiz’s study, no differ-
ences were observed between the two groups in terms of
reduction in pain, as measured with the WOMAC and Le-
quesne’s index questionnaires. Qvistgaard et al.15 failed
to observe any differences between HA and corticoids or
between HA and treatment with placebo. No differences
were in evidence, whether for the WOMAC questionnaire,
Lequesne’s index, or overall outcome assessment by the
patient. Response at 14 days, applying the Osteoarthritis
Research Society International (OARSI) response criteria,
was 53% in patients treated with HA, 56% in the corticoid
group, and 33% in the placebo group. At 28 days, 53% pa-
tients responded to HA, 66% to corticoids, and 44% to
placebo.
Lastly, the review published by Conrozier and Vignon in
200516 concluded that, in view of the absence of placebo-
controlled studies, no conclusive results could be obtained
regarding the efﬁcacy of HA in the treatment of symptomatic
hip OA.
Insofar as the safety of HA treatment is concerned, none
of the studies included reported any adverse effects. The
only complication arose from the HA injection itself, which
sometimes caused local pain, something that seems to
occur more frequently in the case of high-molecular-weight
HA. Consequently, in a number of the studies included, HA
was administered with a local anesthetic (lidocaine)10,12,15.
Discussion
The results of this review indicate that intraarticular HA for
symptomatic treatment of hip OA might have a beneﬁcial ef-
fect in relieving pain. Nevertheless, the absence of compar-
ative studies and other methodologic ﬂaws in the studies
published mean that the relative efﬁcacy of HA vs other
treatments cannot be ascertained.
The efﬁcacy of HA in the treatment of hip OA has been
estimated at 40e60% by many of the studies in this review
(most of them without a control group and a small sample
size). This efﬁcacy was usually attained at 1 month of treat-
ment, though its duration over time is not known. The ab-
sence of a comparison group bars us from ascertaining
the efﬁcacy of HA vis-a`-vis other treatments. The only study
that compared HA against another treatment (intraarticular
corticoids)15 failed to observe any differences between the
two treatments on termination of the study after 3 months.
Furthermore, the follow-up period was not the same in all
the studies included. In some studies it was 3 months11,15,
in others 6 months9,13,14, and in others 1 year12. Similarly,
the point in time when intermediate controls were performed
also differed from study to study, e.g., Vad et al. conducted
no intermediate control12. This means that the outcomes of
all the studies could not be analyzed by reference to the
same follow-up period, if one wanted to include all the stud-
ies in the analysis. While outcomes appear in some cases
as the percentage of patients that experienced animprovement, in others outcomes appear as the percentage
of patients that reported an over-50% improvement in de-
gree of pain according to a visual analog scale (VAS) (Table
II).
Although HA is reported to have lessened pain and im-
proved joint function in most studies, there are discrep-
ancies as to the precise type of treatment that should be
used. Thus, the molecular weight of the HA used is high
in some studies10e13 and low in others9,15. In addition, the
number of doses administered varies among studies:
whereas in some, a single dose was administered, in others
up to three were administered. Still others left administration
of additional doses to the physician’s discretion, depending
upon the therapeutic response, and it is therefore not at all
easy to establish what the appropriate dosage for intraartic-
ular treatment of hip OA should be.
Different criteria are used to assess the efﬁcacy of treat-
ment in the individual studies. Table III sets out the different
scales or scores used to assess study outcomes. Degree of
pain was thus assessed with a Likert-type scale, a VAS, or
the WOMAC questionnaire subscale A. Function was as-
sessed with as many as ﬁve different scales, though the
most widely used was the WOMAC questionnaire, followed
Table II
Description of study efficacy
Reference Efﬁcacy assessment Efﬁcacy
Bragantini
and Molinaroli9
Pain 6 months
16 asymptomatic
17 mild pain
9 moderate pain
7 severe pain
Brocq et al.10 Response deﬁned
as 50% reduction in
Lequesne
59% response
at 30 days
Conrozier et al.11 Pain 43% improvement
Total WOMAC 28.1% improvement
Vad et al.12 Response deﬁned as
50% reduction in
pain and good or
excellent degree
of satisfaction
84% response
at 1 year
Berg and
Olsson13
Response deﬁned
as 40% reduction in
pain with a
5-point reduction
55% at 3 months
44% at 6e8 months
Tikiz et al.14 Low molecular
weight
6 months
Pain 38% improvement
WOMAC 43% improvement
Lequesne 47% improvement
High molecular
weight
6 months
Pain 40% improvement
WOMAC 40% improvement
Lequesne 49% improvement
Qvistgaard et al.15 OARSI criteria
14 days
HA; 53%
Corticoids; 56%
Placebo; 33%
OARSI criteria
28 days
HA; 53%
Corticoids; 66%
Placebo; 44%
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Description of the scales used to assess pain, function, and overall evaluation by both patient and physician
Reference Pain Function Patient self-assessment Physician assessment
Bragantini and Molinaroli9 Likert-type scale Range of joint movement Likert-type scale Likert-type scale
Brocq et al.10 VAS Lequesne
Conrozier et al.11 VAS (0e100) WOMAC VAS (0e100) VAS (0e100)
Vad et al.12 VAS (0e100) AAOS Lower
Limb Core Scale
Likert-type scale
Berg and Olsson13 WOMAC subscale A WOMAC
Tikiz et al.14 VAS (0e100) WOMAC (Likert) VAS (0e100)
Lequesne
Qvistgaard et al.15 VAS (0e100) WOMAC
Lequesne
AAOS: American Academy of Orthopedic Surgeons.by Lequesne’s index. At least two studies14,15 used two dif-
ferent scales to assess function. This disparity in outcome
measurement criteria gives some idea of how difﬁcult it is
to draw conclusions from the results of studies, and is
also one of the most important reasons why a meta-analy-
sis could not be performed.
The only study that compared HA against another differ-
ent treatment15 (intraarticular corticoids) failed to observe
any differences between the two on termination of the study
after 6 months. The absence of a control group in most of
the studies bars proper analysis of the placebo effect which
may be generated by the mere presence of an intervention
per se, as occurred in Qvistgaard’s study. It had the largest
sample size and three comparison groups, namely, HA, cor-
ticoids, and placebo. This study was the only randomized,
double-blind, controlled trial, with 104 patients included.
No differences among the three groups were in evidence
at 3 months of treatment, a ﬁnding that has a decisive inﬂu-
ence when it comes to assessing the available evidence.
It should be mentioned that in some studies simultaneous
treatment with NSAIDs and/or SYSADOAs10,11,14 was per-
mitted, whilst in another study12 the patients followed an ex-
ercise program after treatment with HA, something that
might have interfered in the ﬁnal outcomes. Furthermore,
three studies were excluded for having fewer than 20
patients.17e19
All the studies included, save two14,15, were clinical tri-
als without a comparison group. Despite the fact that al-
most all the papers deﬁned a series of patient inclusion
and exclusion criteria, these were not uniform between
the included studies and some of them did not specify
the way they chose the patients to be included. The ideal
way to select subjects would have been by selecting all
patients who fulﬁlled these criteria from among a random
sample of individuals eligible for inclusion, or by consec-
utively sampling all patients who met the inclusion criteria.
The absence of this control group in all but one study15
means that the effectiveness of HA treatment cannot be
ascertained, inasmuch as one can ascertain its efﬁcacy
but not whether such efﬁcacy is greater or less than
that of other treatments for hip OA. This likewise means
that one cannot establish whether the treatment is safer
or unsafer than others.
Some studies include patients with one or both hips af-
fected9,11. This may pose a problem when it comes to inter-
preting the outcomes. In addition, some studies included
patients with Kellgren and Lawrence grade IV, which means
that these are patients with very severe OA and in ad-
vanced patients, fewer treatments are likely to help. By
the same token, it should also be stressed that there were
some studies10 which included patients with Kellgren andLawrence grade I, patients with scant symptomatology
and little likelihood of improvement in absolute terms.
The results obtained in the different studies included
seem to indicate that injection of HA is a safe technique
for treatment of hip OA. No adverse effects attributable to
the treatment were reported and the only complication
arose from the method used for administering the medica-
tion, i.e., the injection. Provided that this procedure is prop-
erly performed under the necessary aseptic conditions,
there should be no injection-related adverse effects of any
kind although the adverse effect of pain with needle injec-
tion will always be a consideration.
Despite the fact that HA has been proposed as intraartic-
ular treatment of symptomatic kneeOA6,7, its role in the treat-
ment of hip OA is not at all clear, due fundamentally to the
dearth of studies and to the methodologic limitations of those
that have been published. Conclusions drawn on the basis of
available evidence would seem to indicate that in hip OA HA
treatment ameliorates pain and improves function. Neverthe-
less, the lack of comparative studies and the absence of im-
provement vs corticoids or placebo in the most rigorous and
largest-sized clinical trial published to date mean that pru-
dence is advisable when interpreting results, and that, until
fuller information is available, HA treatment should only be
used under careful supervision by the clinician and just in
those cases where other treatments have failed in hip OA.
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